Refine by
Profiling System Articles & Analysis
27 news found
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid ...
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
ByBayer AG
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). The data was presented during a Late-Breaking Clinical Trial session at the 2022 ...
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success EsoCap’s proprietary and unique targeted application technology for the upper ...
Aliso Viejo, CA – June 7, 2022 – Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company’s LOBO® Vascular Occlusion ...
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the appointment of Robert Korn as SVP Global Sales & Marketing. With more than 25 years of sales and marketing experience in the healthcare industry, Mr. Korn enhances the company’s current leadership team as the company accelerates into full ...
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
ByBio-Me
Synergy Biomedical, LLC, a developer of innovative biomaterial products, today announced the launching of BIOSPHERE® MIS II, Next Generation Minimally Invasive Bone Graft Delivery System. Synergy continues to add solutions for surgeons with new innovative biomaterial products to an already successful portfolio. Leveraging off the proven success of the first-generation design, BIOSPHERE® ...
LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients LANTERN study manuscript wins ARS Annual Meeting 2021 Clinical Science Maurice Cottle Award Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of ...
Recognized for its growth potential, Sonic Incytes Medical Corp. has been named a top technology company in the 19th Annual “Ready to Rocket” list published by Rocket Builders. Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top ...
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application. Since launching in 2018, the New York City-based company has focused its efforts on multiomic ...
ByImmunai
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-leading microbiome technology expertise to bring new therapeutics to this ...
BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed ...
Aliso Viejo, CA- December 16, 2020 – Okami Medical Inc., a medical device company, today announced the expansion of its LOBO™ Vascular Occlusion System product line with the U.S. FDA 510(k) clearance of the LOBO-5 Vascular Occluder. The LOBO (LOw-profile Braided Occluder) system is uniquely designed to provide interventional physicians with a single-device, ...
NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will ...
Furthering its mission to transform the treatment of aortic disorders, Endologix, Inc. (OTC: ELGXQ) (“Endologix” or the “Company”) today announced the first implant of its recently approved ALTO® endograft outside of the United States, completed by Andrew Holden, MD, and Andrew Hill, MD, of Auckland City Hospital, Auckland, New Zealand. “With the 7 mm infrarenal ...
Aliso Viejo, CA- June 24, 2020 – Okami Medical Inc., announced today the close of a Series D financing totaling $7.2 million. The financing was led by U.S. Venture Partners and was joined by members of Okami’s board of directors and medical device industry veterans. The financing provides Okami, the second portfolio company of medical device incubator Inceptus Medical LLC, with ...
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, Immunai has mapped out millions of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. The company is also announcing $20M in seed ...
ByImmunai
Cerus Endovascular Ltd., a privately held, commercial stage medical device company, today announced that it has received CE Mark approval for its 021 Contour Neurovascular System, compatible with smaller commercially available 021 microcatheters for the treatment of saccular intracranial aneurysms. The Contour Neurovascular System is a unique, fine mesh braid that is deployed across the neck of ...